Belgium: Punching Well Above its Weight in Clinical Trials
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Address: Avenue Ariane 16 1200 Brussels Belgium
Tel: +32 (0)2 773 33 11
Web: http://www.boehringer-ingelheim.be/
The Boehringer Ingelheim group
Our group, established in Ingelheim (Germany), has 137 subsidiaries across 47 countries and approximately 41,500 employees, of which nearly 5,000 are active in research and development.
Since its foundation in 1885, the group is still wholly owned by the founding family and focused on researching, developing and producing and marketing of new products with high added value for medical use, also in veterinary medicine.
In Belgium and Luxembourg Boehringer Ingelheim employs over 250 staff working in the sales and distribution of pharmaceutical products for humans and animals and in clinical research.
With research as our main growth engine, developing our laboratories breakthrough medicines for use in diverse areas such as pneumology, cardiology, rheumatology, neurology, virology and oncology. Boehringer Ingelheim also develops products for self-medication and phyto-pharmaceuticals, and a series products for veterinary use. Our activities extend also to the chemical and biopharmaceutical manufacturing. Our main activity in Belgium includes the sale and distribution of pharmaceutical products for humans and animals, as well as clinical research.
Despite a population size of only 11.4 million (ninth in Europe), Belgium is the continent’s fifth biggest spender on R&D, behind only Germany, Switzerland, the UK, and France according to…
Xavier De Cuyper introduces the Federal Agency for Medicines & Health Products (FAMHP) and the essential role it plays in Belgium’s healthcare regulatory framework since being founded in 2007. De…
Chantal Depondt, president of the Belgian Neurological Society (BNS), introduces the mission of the professional association and offers her insights into the healthcare and research dynamics surrounding neurological diseases. Depondt…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on…
Brecht Vanneste, associate VP and managing director of MSD in Belgium and Luxembourg, highlights the strategic significance of the affiliate as an important location for early-stage clinical trials and home…
Teun Grooters, co-founder and CEO of Arega – the exclusive distributor of Teva generics in Belgium – tells the story of the newly founded pharmaceutical company and shares his future…
Belgian Former Minister of Social Affairs, Public Health and Asylum & Migration Maggie de Block outlines some of the key reforms her Ministry has rolled out since she took office…
Frank Swaelens, general manager of IQVIA in Belgium and Luxembourg, offers insights into the healthcare and life science ecosystem of Belgium and highlights the opportunities that exist for the country…
Françoise Smets, dean of the Faculty of Medicine and Dentistry at Université Catholique de Louvain (UCLouvain), introduces the innovation and research capacity of the institution as the top-ranking French-speaking university…
Teva Pharma Belgium’s Eric Deschepper outlines how the global group’s restructuring has impacted its Belgian operations, its realignment from a pure generics to a specialty pharma player, and how the…
Over the past few decades, pharma multinationals have been increasingly drawn to the highly cost-competitive markets of Central Eastern Europe (CEE) and Asia to situate major manufacturing sites. However, despite…
See our Cookie Privacy Policy Here
